Ventus Therapeutics CEO Marcelo Bigal

Novo Nordisk scoops up Ventus' lead NLRP3 drug candidate for $70M

Similarly, Ventus CEO Marcelo Bigal, M.D., Ph.D. said that the deal marked an “important collaboration” for the company and noted that Novo ...

Vineeta Agarwala on X: ""A Reawakening of Small Molecule Drug ...

"A Reawakening of Small Molecule Drug Development" - great perspective from Marcelo Bigal, CEO @Ventus_Tx Highlighting the power of ...

Intelligence By Design - The Medicine Maker

Here, we speak to Marcelo Bigal, President and Chief Executive Officer at Ventus Therapeutics, Jo Viney, founder, President and Chief ...

Ventus Therapeutics Inc., Montréal - [LSUS] Life-Sciences-USA.com

ReSOLVE™ drug discovery platform. Person, Bigal, Marcelo (Ventus Therapeutics 202003– CEO + Versant Ventures 202003– Venture Partner based in Montréal).

Press release - FTQ

Ventus Therapeutics Closes $140 Million Series C Financing ... Marcelo Bigal, M.D., Ph.D., president and CEO of Ventus. The Series ...

Ventus Therapeutics to Present at 2024 Bloom Burton & Co ...

... therapeutics for immunology, inflammation, and neurology disorders, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.

Ventus Therapeutics Company Profile - Datanyze

Funding History. Ventus Therapeutics raised a total of $300 M in funding over 3 rounds. Marcelo Bigal. CEO. Marcelo ...

Ventus Therapeutics U.S. secures $100M Series B led by RA Capital

Ventus Therapeutics U.S. secured US $100M Series B from RA Capital Management ... Marcelo Bigal, M.D., Ph.D., president and CEO of Ventus. “We ...

Ventus Therapeutics to Present at the 41st Annual J.P. Morgan ...

... President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on ...

With $140M series C, Ventus 'Resolves' to advance discovery ...

Ventus Therapeutics Inc ... The second drug program is a brain-penetrant NLRP3 inhibitor. Marcelo Bigal, CEO, Ventus.

Novo Nordisk joins Novartis, Roche in NLRP3 arena, betting $70M ...

Marcelo Bigal, Ventus Therapeutics CEO. September 29, 2022 07:08 AM ... The way Ventus CEO Marcelo Bigal sees it, the alliance has a ...

Novo Nordisk Inks $700 Million Deal with Ventus Therapeutics

... Marcelo Bigal, president and CEO, Ventus Therapeutics, in the release. “We believe Novo Nordisk is the ideal partner to advance our lead ...

Chasing Novartis and Roche, Ventus banks $140M ... - Fierce Biotech

Ventus Therapeutics Marcelo Bigal, president and CEO of Ventus Therapeutics (Ventus Therapeutics). The money keeps flowing into Ventus ...

Ventus Therapeutics | C&EN Global Enterprise - ACS Publications

... Ventus Therapeutics CEO Marcelo Bigal, cofounder Hao Wu, and cofounder Judy Lieberman. Bottom row, from left: cofounder Thomas Tuschl, Ventus ...

Ventus and Novo Nordisk enter NLRP3 inhibitor development deal

Ventus Therapeutics and Novo Nordisk have signed a licence ... Ventus president and CEO Marcelo Bigal said: “This is an important ...

Montreal's Ventus Therapeutics strikes US$700-million-plus deal ...

Montreal's Ventus Therapeutics strikes US$700-million-plus deal with pharma giant Novo Nordisk ... Ventus CEO Marcelo Bigal said drug candidates ...

Ventus Therapeutics closes $140 million Series C financing

Ventus Therapeutics Closes $140M Series C Financing Round

D., of SoftBank Investment Advisers will join the Ventus Board of Directors. Led by Marcelo Bigal, M.D., Ph.D., president and CEO, Ventus is ...

Ventus Therapeutics to Present at the Stifel 2023 Healthcare ...

... that its President and Chief Executive Officer Marcelo Bigal, M.D., Ph.D., will present at the Stifel 2023 Healthcare Conference in New York. Dr. Bigal's ...

Ventus Therapeutics Enters Exclusive Development and License ...

... Marcelo Bigal, M.D., Ph.D., President and CEO of Ventus. “We believe Novo Nordisk is the ideal partner to advance our lead NLRP3 program in ...